Viewing Study NCT02299505


Ignite Creation Date: 2025-12-25 @ 3:11 AM
Ignite Modification Date: 2026-02-24 @ 10:55 AM
Study NCT ID: NCT02299505
Status: COMPLETED
Last Update Posted: 2022-02-09
First Post: 2014-11-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE1 View
Observational Models:
Time Perspective List:
Who Masked List: